Department of Immunology, Institute for Biological Research "Sinisa Stankovis", University of Belgrade, Belgrade, Serbia.
Immunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, Spain.
Curr Pharm Des. 2017;23(18):2623-2643. doi: 10.2174/1381612823666170214120708.
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
基于细胞的耐受治疗是治疗自身免疫性疾病和移植排斥反应的一种很有前途的方法。调节性 T 细胞和耐受原性树突状细胞在疾病的实验模型中已被特别用于治疗各种自身免疫性疾病。尽管其中一些细胞已经在有限数量的临床试验中进行了测试,但在自身免疫动物模型中进行耐受细胞的临床前研究仍然是必要的。这篇综述将重点讨论从实验动物模型研究中获得的数据与基于耐受细胞的治疗在人类中的应用的相关性。此外,还将讨论进一步提高耐受细胞制备的前景,以增强细胞的抑制活性和稳定性。